Phenotypes associated with this allele

• Allele Symbol: Peli2^tm1.1Arte
• Allele Name: targeted mutation 1.1, TaconicArtemis
• Allele ID: MGI:6401217
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Peli2^tm1.1Arte/Peli2^tm1.1Arte	involves: C57BL/6	MGI:6401400

Genotype
MGI:6401400

hm1

• Allelic Composition: Peli2^tm1.1Arte/Peli2^tm1.1Arte
• Genetic Background: involves: C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cellular

increased macrophage apoptosis ( J:265431 )

• increased pyroptosis of bone marrow-derived macrophages (BMDMs) after LPS+ATP stimulation and after LPS+nigericin stimulation

• normal response by bone marrow-derived macrophages (BMDMs) to LPS+cholera toxin B (CTB) stimulation

hematopoietic system

increased macrophage apoptosis ( J:265431 )

• increased pyroptosis of bone marrow-derived macrophages (BMDMs) after LPS+ATP stimulation and after LPS+nigericin stimulation

• normal response by bone marrow-derived macrophages (BMDMs) to LPS+cholera toxin B (CTB) stimulation

homeostasis/metabolism

abnormal circulating cytokine level ( J:265431 )

• reduced interleukin 1-beta serum levels after intraperitoneal administration of non-lethal LPS dose

• normal IL-6, TNF, CXCL1, and RANTES levels after intraperitoneal administration of non-lethal LPS dose

decreased circulating interleukin-1 beta level ( J:265431 )

• reduced serum levels after intraperitoneal administration of non-lethal LPS dose

immune system

increased macrophage apoptosis ( J:265431 )

• increased pyroptosis of bone marrow-derived macrophages (BMDMs) after LPS+ATP stimulation and after LPS+nigericin stimulation

• normal response by bone marrow-derived macrophages (BMDMs) to LPS+cholera toxin B (CTB) stimulation

abnormal circulating cytokine level ( J:265431 )

• reduced interleukin 1-beta serum levels after intraperitoneal administration of non-lethal LPS dose

• normal IL-6, TNF, CXCL1, and RANTES levels after intraperitoneal administration of non-lethal LPS dose

decreased circulating interleukin-1 beta level ( J:265431 )

• reduced serum levels after intraperitoneal administration of non-lethal LPS dose

abnormal cytokine secretion ( J:265431 )

• reduced interleukin 1-beta secretion by bone marrow-derived macrophages (BMDMs) after LPS, LPS+ATP, LPS+nigericin, LPS+alum, zymosan+ATP, and Citrobacter rodentium, Escherichia coli, or Pseudomonas aeruginosa stimulation

• normal CXCL1 secretion by bone marrow-derived macrophages (BMDMs) after Escherichia coli stimulation

• normal IL-6 secretion by bone marrow-derived macrophages (BMDMs) after Pseudomonas aeruginosa stimulation

decreased interleukin-1 beta secretion ( J:265431 )

• by bone marrow-derived macrophages (BMDMs) after LPS, LPS+ATP, LPS+nigericin, LPS+alum, zymosan+ATP, and Citrobacter rodentium, Escherichia coli, or Pseudomonas aeruginosa stimulation

• normal response by bone marrow-derived macrophages (BMDMs) to double stranded DNA (poly (dA:dT)), flagellin and LPS+cholera toxin B (CTB) stimulation

• by peritoneal macrophages after LPS+ATP stimulation

decreased interleukin-18 secretion ( J:265431 )

• by bone marrow-derived macrophages (BMDMs) after LPS+ATP, LPS+nigericin, and Pseudomonas aeruginosa stimulation

mortality/aging

decreased susceptibility to induced morbidity/mortality ( J:265431 )

• 50% survival (wildtype: 0%) after intraperitoneal administration of lethal LPS dose